Drug Pipeline

Visugromab RDE (recommended dose for expansion) Clinical Trials

Data updated daily from ClinicalTrials.gov — last refresh 2026-06-12
5
Active Studies
4
Recruiting
1
Phase 3
1
Top Sponsors
3
Changes, 30 Days
What Changed in the Last 30 Days
DetectedTrialChange
2026-06-10 NCT07246863
Trial Investigating Visugromab and Nivolumab With or Without Docetaxel in 2L Treatment of…		 Trial sites expanded: 15 -> 25 locations
2026-05-21 NCT07112196
Visugromab in Cachexia International Trial		 Trial sites expanded: 7 -> 34 locations
2026-05-14 NCT07098988
Trial Investigating Visugromab in Combination With Immunochemotherapy in 1L Treatment of…		 Trial sites expanded: 25 -> 37 locations
Active Studies by Phase
Phase 2/3
1
Phase 2
3
Phase 1/2
1
Active Trials
NCT IDTitleConditionStatus
Phase 2/3
NCT07112196 Visugromab in Cachexia International Trial Cancer-associated Cachexia Recruiting
Phase 2
NCT07219459 Visugromab, Nivolumab and Lenvatinib Compared to Double Placebo and Lenvatinib in… Unresectable or Metastatic Hepatocellular Carcinoma Recruiting
NCT07098988 Trial Investigating Visugromab in Combination With Immunochemotherapy in 1L Treatment of… Metastatic Non-Squamous Non-Small Cell Lung Cancer Recruiting
NCT07246863 Trial Investigating Visugromab and Nivolumab With or Without Docetaxel in 2L Treatment of… Metastatic Non-Squamous Non-Small Cell Lung Cancer Recruiting
Phase 1/2
NCT04725474 First-in-Human Study of the GDF-15 Neutralizing Antibody Visugromab (CTL-002) in Patients… Solid Tumor, Adult Active, Not Recruiting
Sponsors Running Visugromab RDE (recommended dose for expansion) Trials
CatalYm GmbH (5)
Disease Areas
Non-Small Cell Lung Cancer (NSCLC) (2) Lung Cancer (2) Liver Cancer (1)
Get alerts when Visugromab RDE (recommended dose for expansion) trials change
Status changes, date slips, and new filings — detected daily, delivered to your inbox.
Start monitoring free